Adjuvant mitotane for adrenocortical cancer - Working through uncertainty

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 6, 2009, Pages 1879-1880

  Terzolo, M ^a,d   Fassnacht, M ^c   Ciccone, G ^b   Allolio, B ^c   Berruti, A ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d Azienda Sanitaria Ospedaliera San Luigi   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MITOTANE;

ABSENCE OF SIDE EFFECTS; ADRENAL CORTEX CARCINOMA; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; DRUG WITHDRAWAL; FOLLOW UP; HAZARD RATIO; HUMAN; LOW DRUG DOSE; MULTIVARIATE ANALYSIS; NOTE; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT DURATION; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

EID: 66749174642     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-0120     Document Type: Note

References (10)

1. Huang H, Fojo T 2008 Commentary: adjuvant mitotane for adrenocortical cancer - a recurring controversy. J Clin Endocrinol Metab 93:3730-3732
2. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A 2007 Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356:2372-2380 (Pubitemid 46883771)
3. Allolio B, Fassnacht M 2006 Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 91:2027-2037
4. Hahner S, Fassnacht M 2005 Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs 6:386-394 (Pubitemid 40561415)
5. Schteingart DE 2007 Adjuvant mitotane therapy of adrenal cancer - use and controversy. Editorial. N Engl J Med 356:2415-2418
6. Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre T, Goldberg RM, De Gramont A 2005 Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23:8664-8670 (Pubitemid 46211509)
7. Daffara F, De Francia S, Reimondo G, Zaggia B, Aroasio E, Porpiglia F, Volante M, Termine A, Di Carlo F, Dogliotti L, Angeli A, Berruti A, Terzolo M 2008 Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer 15:1043-1053
8. Faggiano A, Leboulleux S, Young J, Schlumberger M, Baudin E 2006 Rapidly progressing high o,p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results. Clin Endocrinol (Oxf) 64:110-113
9. Terzolo M, Berruti A 2008 Adjunctive treatment of adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obes 15:221-226
10. Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, Dousset B, Bertagna X, Bertherat J 2006 Bioclinical features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors from a series of 202 consecutive patients. J Clin Endocrinol Metab 91:2650-2655 (Pubitemid 44024632)